Advertisement
ABBV vs MRK
Which Stock Would AI Choose? AbbVie (ABBV) vs. Merck & Co. (MRK) Stock Comparison
Key Takeaways
- ABBV has delivered solid year-to-date returns of approximately 12% amid strong demand for its immunology portfolio, including Skyrizi and Rinvoq.
- MRK has outperformed with year-to-date gains near 21-24% and one-year returns exceeding 60%, driven primarily by Keytruda expansion and pipeline progress.
- ABBV announced a $10.1 billion acquisition of Apogee Therapeutics in June 2026, bolstering its immunology pipeline.
- MRK secured multiple regulatory approvals and positive late-stage trial results for Keytruda combinations and other assets in recent weeks.
- Both stocks trade in the healthcare sector with exposure to high-growth therapeutic areas, though MRK shows stronger recent momentum while ABBV offers post-Humira diversification.
- Relative performance highlights trade-offs between ABBV’s acquisition-driven catalysts and MRK’s established oncology leadership.
Introduction
AbbVie Inc. (ABBV) and Merck & Co., Inc. (MRK) represent two leading biopharmaceutical companies whose stocks often attract attention from investors seeking exposure to innovative therapies in immunology and oncology. This comparison examines their recent stock behavior, business drivers, and market positioning in the current environment. Portfolio managers, sector-focused traders, and long-term investors evaluating healthcare allocations may find the analysis relevant for assessing relative opportunities between established revenue generators and those navigating patent transitions or growth acceleration.
ABBV Overview and Recent Performance
AbbVie specializes in immunology, oncology, and neuroscience treatments, with key products Skyrizi and Rinvoq driving growth following the Humira patent expiration. In recent market activity, ABBV shares have traded near 52-week highs around $252–$255, reflecting investor focus on robust demand for its newer immunology agents. The company completed a $10.1 billion acquisition of Apogee Therapeutics in June 2026, expanding its pipeline in inflammatory conditions. Sentiment has remained constructive amid analyst optimism and expectations for continued double-digit revenue contribution from Skyrizi and Rinvoq, supporting year-to-date gains of roughly 12% despite broader market fluctuations.
MRK Overview and Recent Performance
Merck & Co. maintains leadership in oncology through Keytruda while advancing vaccines and other therapeutic areas. Recent weeks have featured expanded regulatory approvals for Keytruda combinations and positive Phase 3 results for additional candidates, reinforcing pipeline momentum. MRK shares closed near $126 on July 8, 2026, with year-to-date advances approaching 21–24% and one-year returns exceeding 60%. Multiple analyst price target increases during the period have supported sentiment, though the stock has experienced typical volatility associated with large-cap pharma names navigating competitive and regulatory landscapes.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots designed for varying market conditions. Tickeron offers hundreds of AI Trading Bots that trade thousands of different tickers, yet only the most suitable and effective ones based on current data earn placement in the Trending AI Robots section. Available bots feature a wide range of trading styles, strategies, timeframes, performances, and statistics, with many demonstrating success rates between 60% and 85% across diverse market environments and profit factors often exceeding 1.5 in optimized setups. All the AI trading bots have different trading styles, strategies, timeframes, performances, statistics, and sets of tickers they trade. Review the full selection to identify bots aligned with individual risk preferences and objectives. Trending AI Robots
Head-to-Head Comparison
ABBV and MRK both operate in the biopharmaceutical space but differ in core exposures: ABBV emphasizes post-patent diversification through immunology agents, while MRK relies heavily on Keytruda for oncology revenue. Recent momentum favors MRK on absolute returns, though ABBV’s acquisition provides a distinct near-term catalyst. Risk factors include patent cliffs and pricing pressure for both, with MRK facing greater concentration risk around a single product. Sector sentiment remains supportive of innovative pipelines, yet relative performance reflects contrasting growth trajectories—ABBV balancing transition risks with new assets versus MRK extending leadership in established indications.
Tickeron AI Verdict
Based on observable trend consistency, relative returns, and catalyst visibility over recent weeks, Tickeron’s AI models indicate a probabilistic preference for MRK in the current environment due to stronger momentum and multiple positive pipeline developments. ABBV remains competitive through its acquisition and immunology growth, potentially offering value in scenarios prioritizing diversification. Outcomes depend on evolving market conditions and execution on announced plans.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Hold and MRK is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green whileMRK’s FA Score has 3 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- MRK’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while MRK’s TA Score has 4 bullish TA indicator(s).
- ABBV’s TA Score: 4 bullish, 5 bearish.
- MRK’s TA Score: 4 bullish, 5 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а -2.73% price change this week, while MRK (@Pharmaceuticals: Major) price change was -1.89% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.25%. For the same industry, the average monthly price growth was +11.55%, and the average quarterly price growth was +7.59%.
Reported Earning Dates
ABBV is expected to report earnings on Jul 31, 2026.
MRK is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-2.25% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ABBV | MRK | ABBV / MRK | |
| Capitalization | 431B | 305B | 141% |
| EBITDA | 16.9B | 19.4B | 87% |
| Gain YTD | 9.362 | 19.154 | 49% |
| P/E Ratio | 119.66 | 34.82 | 344% |
| Revenue | 62.8B | 65.8B | 95% |
| Total Cash | N/A | N/A | - |
| Total Debt | 72.9B | 49.1B | 148% |
ABBV | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 77 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 64 Fair valued | 14 Undervalued | |
PROFIT vs RISK RATING 1..100 | 7 | 47 | |
SMR RATING 1..100 | 1 | 47 | |
PRICE GROWTH RATING 1..100 | 16 | 20 | |
P/E GROWTH RATING 1..100 | 20 | 5 | |
SEASONALITY SCORE 1..100 | 21 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRK's Valuation (14) in the Pharmaceuticals Major industry is somewhat better than the same rating for ABBV (64). This means that MRK’s stock grew somewhat faster than ABBV’s over the last 12 months.
ABBV's Profit vs Risk Rating (7) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (47). This means that ABBV’s stock grew somewhat faster than MRK’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (47). This means that ABBV’s stock grew somewhat faster than MRK’s over the last 12 months.
ABBV's Price Growth Rating (16) in the Pharmaceuticals Major industry is in the same range as MRK (20). This means that ABBV’s stock grew similarly to MRK’s over the last 12 months.
MRK's P/E Growth Rating (5) in the Pharmaceuticals Major industry is in the same range as ABBV (20). This means that MRK’s stock grew similarly to ABBV’s over the last 12 months.
| ABBV | MRK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 41% | 2 days ago 49% |
| Stochastic ODDS (%) | 2 days ago 67% | 2 days ago 62% |
| Momentum ODDS (%) | 2 days ago 52% | 2 days ago 49% |
| MACD ODDS (%) | 2 days ago 42% | 2 days ago 58% |
| TrendWeek ODDS (%) | 2 days ago 50% | 2 days ago 49% |
| TrendMonth ODDS (%) | 2 days ago 63% | 2 days ago 54% |
| Advances ODDS (%) | 17 days ago 58% | 17 days ago 54% |
| Declines ODDS (%) | 2 days ago 48% | 6 days ago 51% |
| BollingerBands ODDS (%) | 2 days ago 40% | 2 days ago 57% |
| Aroon ODDS (%) | 2 days ago 64% | 2 days ago 60% |
Advertisement